nach oben

CardioVascular and Interventional Radiology

Erschienen in:

09.03.2020 | Clinical Investigation

Transarterial Ethanol Ablation for Small Hepatocellular Carcinoma (≤ 3 cm): A Comparative Study Versus Radiofrequency Ablation

verfasst von: Simon Chun Ho Yu, Joyce Wai Yi Hui, Charing Ching Ning Chong, Cheuk Man Chu, Sunny Cheung, John Wong, Kit Fai Lee

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective was to evaluate the local treatment efficacy of transarterial ethanol ablation (TEA) as compared to radiofrequency ablation (RFA) for small hepatocellular carcinoma (HCC).

Materials and Methods

This was a retrospective study between January 2005 and April 2017, in which the treatment outcomes of all patients who received either percutaneous TEA or RFA for HCC tumors of size ≤ 3 cm, of Child–Pugh grade A or B, received no prior treatment other than surgical resection, were compared. For TEA, a mixture of absolute ethanol and ethiodized oil at a proportion of 1:2 by volume was administered superselectively into the tumor via a microcatheter placed at the feeding arteries. The TEA group and the RFA group consisted of 68 consecutive patients (88 treated target tumors) and 129 consecutive patients (129 tumors), respectively.

Results

Technical success was achieved in all the target tumors in both groups. Grade 3 complication (CIRSE Classification) of prolonged fever occurred in 3 cases with multi-focal and large tumors in the TEA group. There was no statistically significant difference in complete response rate between the TEA group (84/88 or 95.5%) and the RFA group (188/195 or 96.4%) (p = 0.7). Time to progression in the TEA group [median 11.9 months, interquartile range (IQR) 5.6–18 months] was not statistically different from that in the RFA group (median 9.5 months, IQR 3.5–18.7 months) (p = 0.773).

Conclusion

TEA could be an effective alternative of RFA for the local treatment of small HCC; it is especially valuable for tumors of unfavorable location.

European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef

Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50.CrossRef

Goldberg SN, Hahn PF, Tanabe KK, et al. Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol. 1998;9(1 Pt 1):101–11. https://doi.org/10.1016/S1051-0443(98)70491-9.CrossRefPubMed

Lu DS, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol. 2003;14:1267–74. https://doi.org/10.1097/01.RVI.0000092666.72261.6B.CrossRefPubMed

Cucchetti A, Piscaglia F, Cescon M, Ercolani G, Pinna AD. Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol. 2013;19:4106–18. https://doi.org/10.3748/wjg.v19.i26.4106.CrossRefPubMedPubMedCentral

Kondo Y, Yoshida H, Shiina S, Tateishi R, Teratani T, Omata M. Artificial ascites technique for percutaneous radiofrequency ablation of liver cancer adjacent to the gastrointestinal tract. Br J Surg. 2006;93:1277–82. https://doi.org/10.1002/bjs.5374.CrossRefPubMed

Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation with artificial ascites for hepatocellular carcinoma in the hepatic dome: initial experience. AJR. 2008;190:91–8. https://doi.org/10.2214/AJR.07.2384.CrossRefPubMed

Lencioni R, Llovet JM. Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead? J Hepatol. 2005;43:377–80. https://doi.org/10.1016/j.jhep.2005.06.001.CrossRefPubMed

Lencioni R, Crocetti L, Cioni D, et al. Single-session percutaneous ethanol ablation of early-stage hepatocellular carcinoma with a multi-pronged injection needle: results of a pilot clinical study. J Vasc Interv Radiol. 2010;21:1533–8. https://doi.org/10.1016/j.jvir.2010.06.019.CrossRefPubMed

10.

Giorgio A, Di Sarno A, De Stefano G, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res. 2011;31:2291–5.PubMed

11.

Yu SC, Chan CT. Transarterial ethanol ablation of cirrhotic liver with lipiodol-ethanol mixture: safety and efficacy study in rats. Investig Radiol. 2006;41:609–17. https://doi.org/10.1097/01.rli.0000223884.05289.c3.CrossRef

12.

Yu SCH, Leung TWT, Lau WY, et al. A comparison of three transarterial lipiodol-based formulations for hepatocellular carcinoma: in vivo bio-distribution study in human. Cardiovasc Intervent Radiol. 2008;31(2):289–98.CrossRef

13.

Yu SCH, Hui EP, Wong J, et al. Transarterial ethanol ablation of hepatocellular carcinoma with lipiodol-ethanol mixture: phase II Study. J Vasc Interv Radiol. 2008;19:95–103. https://doi.org/10.1016/j.jvir.2007.08.038.CrossRefPubMed

14.

Yu SC, Hui JW, Hui EP, et al. Embolization efficacy and treatment effectiveness of transarterial therapy for unresectable hepatocellular carcinoma: a case-controlled comparison of transarterial ethanol ablation with lipiodol-ethanol mixture versus transcatheter arterial chemoembolization. J Vasc Interv Radiol. 2009;20:352–9. https://doi.org/10.1016/j.jvir.2008.12.407.CrossRefPubMed

15.

Yu SC, Hui JW, Hui EP, et al. Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. Radiology. 2014;270:607–20. https://doi.org/10.1148/radiol.13130498.CrossRefPubMed

16.

Yu SCH, Lau TWW, Tang P, et al. Mechanism and natural course of tumor involution in hepatocellular carcinoma following transarterial ethanol ablation. Cardiovasc Intervent Radiol. 2016;39:1136–43. https://doi.org/10.1007/s00270-016-1360-z.CrossRefPubMed

17.

Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable? Cancer. 2009;115:616–23. https://doi.org/10.1002/cncr.24050.CrossRefPubMed

18.

Riaz A, Memon K, Miller FH, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54:695–704. https://doi.org/10.1016/j.jhep.2010.10.004.CrossRefPubMed

19.

Salem R, Lewandowski RJ, Gates VL, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22(3):265–78. https://doi.org/10.1016/j.jvir.2010.10.029.CrossRefPubMedPubMedCentral

20.

Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the Cirse classification system. Cardiovasc Intervent Radiol. 2017;40:1141–6.CrossRef

21.

Castaneda F, Kinne RKH. Ethanol treatment of hepatocellular carcinoma: high potentials of low concentrations. Cancer Biol Ther. 2004;3:430–3. https://doi.org/10.4161/cbt.3.5.806.CrossRefPubMed

22.

Tapani E, Taavisainen M, Lindros K, Vehmas T, Lehtonen E. Toxicity of ethanol in low concentrations. Acta Radiol. 1996;37:923–6. https://doi.org/10.3109/02841859609175470.CrossRefPubMed

23.

Neuman MG, Shear NH, Cameron RG, Katz G, Tribelli C. Ethanol-induced apoptosis in vitro. Clin Biochem. 1999;32:547–55. https://doi.org/10.1016/S0009-9120(99)00054-5.CrossRefPubMed

24.

Higuchi H, Adachi M, Miura S, Gores GJ, Ishii H. The mitochondrial permeability transition contributes to acute ethanol-induced apoptosis in rat hepatocytes. Hepatology. 2001;34:320–8. https://doi.org/10.1053/jhep.2001.26380.CrossRefPubMed

25.

Minana JB, Gomez-Cambronero L, Lloret A, et al. Mitochondrial oxidative stress and CD95 ligand: a dual mechanism for hepatocyte apoptosis in chronic alcoholism. Hepatology. 2002;35:1205–14. https://doi.org/10.1053/jhep.2002.32969.CrossRefPubMed

26.

Kan Z, Ivancev K, Lunderquist A. Peribiliary plexa-important pathways for shunting of iodized oil and silicon rubber solution from the hepatic artery to the portal vein: an experimental study in rats. Investig Radiol. 1994;29(7):671–6.CrossRef

27.

Kan Z, Wallace S. Transcatheter liver lobar ablation: an experimental trial in an animal model. Eur Radiol. 1997;7(7):1071–5.CrossRef

28.

Tanaka K, Okazaki H, Nakamura S, et al. Hepatocellular carcinoma: treatment with a combination therapy of transcatheter arte rial embolization and percutaneous ethanol injection. Radiology. 1991;179(3):713–7.CrossRef

29.

Tanaka K, Nakamura S, Numata K, et al. Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization. Radiology. 1992;2:457–60.CrossRef

Titel: Transarterial Ethanol Ablation for Small Hepatocellular Carcinoma (≤ 3 cm): A Comparative Study Versus Radiofrequency Ablation
verfasst von: Simon Chun Ho Yu
Joyce Wai Yi Hui
Charing Ching Ning Chong
Cheuk Man Chu
Sunny Cheung
John Wong
Kit Fai Lee
Publikationsdatum: 09.03.2020
Verlag: Springer US
Erschienen in: CardioVascular and Interventional Radiology / Ausgabe 5/2020
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-020-02426-4

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Transarterial Ethanol Ablation for Small Hepatocellular Carcinoma (≤ 3 cm): A Comparative Study Versus Radiofrequency Ablation